InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.
The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.
The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.
InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.
Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。